Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib added to docetaxel + carboplatin as first-line treatment for ovarian, fallopian tube, or primary peritoneal carcinoma
ISRCTN30851756Phase 2Completed
- Sponsor
- VU University Medical Center (The Netherlands)
- Start
- Nov 2002
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of celecoxib in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by VU University Medical Center (The Netherlands). Primary endpoints: Response rate and Progression-free survival. Started Nov 2002; status: completed.
02
Drugs
celecoxib
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ISRCTN30851756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN30851756.